These results demonstrated that both CD4+ T and CD8+ T cells played an essential role in the anticancer efficacy of our combination treatment, supporting the rationale of using nMOF-mediated RT to enhance checkpoint blockade cancer immunotherapy. The gene discussed is CD4; the disease is cancer.